{"product_id":"biocause-swot-analysis","title":"Hubei Biocause Pharmaceutical SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eMaps out Hubei Biocause Pharmaceutical’s market strengths, operational gaps, and risks\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eFacilitates interactive planning with a structured, at-a-glance view for Hubei Biocause.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eHubei Biocause Pharmaceutical SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThe displayed preview offers a glimpse of the exact Hubei Biocause Pharmaceutical SWOT analysis. This is the complete document that becomes accessible immediately after purchase. Expect thorough research and actionable insights presented in a clear, organized format. The full version includes all details and is ready for your strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical faces fierce competition. Our initial analysis reveals key strengths, like its established market presence. We've also identified areas for improvement, including supply chain vulnerabilities. This snippet highlights critical opportunities and potential threats in the dynamic pharmaceutical sector. But, what's the whole picture? \u003c\/p\u003e\n\u003cp\u003eWant the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical boasts a diverse product portfolio, covering APIs, pharmaceutical preparations, and medical devices. This broad scope reduces the risk tied to any single product. The variety helps the company cater to different market demands, enhancing its market position. In 2024, diversified product lines contributed to a 15% revenue growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Key Therapeutic Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical's focus on cardiovascular, cerebrovascular, and endocrine diseases allows for specialized expertise. This targeted approach can lead to efficient R\u0026amp;D, potentially improving market penetration. In 2024, the global cardiovascular drugs market was valued at approximately $100 billion. Focusing on these areas can create a strong market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eActive involvement in research and development (R\u0026amp;D) signals Hubei Biocause Pharmaceutical's dedication to innovation and expansion of its product pipeline. Robust R\u0026amp;D is vital for creating new pharmaceutical products, which is critical for staying ahead of the competition. This capability offers opportunities to find and introduce innovative therapies. In 2024, the company invested $50 million in R\u0026amp;D, a 15% increase from the previous year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical's manufacturing expertise indicates well-established production processes and infrastructure. This capability is crucial for product quality, consistency, and supply chain reliability. Control over production costs and timelines is enhanced through in-house manufacturing. In 2024, the pharmaceutical manufacturing sector in China saw a 12% increase in output. This growth highlights the importance of robust manufacturing. This strengthens Hubei Biocause's position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, Chinese pharmaceutical manufacturing output increased by 12%.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eReliable manufacturing ensures product quality and supply chain stability.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eIn-house production offers control over costs and timelines.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Market Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical's established market presence, stemming from its pharmaceutical product sales, indicates a robust distribution network and customer base. This existing infrastructure simplifies market access and streamlines sales operations, offering a significant advantage. This foundation is crucial for introducing new products and broadening market share, supported by consistent sales figures. For instance, in 2024, the company reported a 15% increase in sales compared to the previous year, demonstrating the strength of its market position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eExisting distribution network.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eEstablished customer base.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFacilitates market access.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSupports new product launches.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHubei's 2024: Growth, Innovation, and Market Impact\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHubei Biocause possesses a varied product range, reducing risk and addressing varied demands; contributing to 15% revenue growth in 2024.\u003c\/p\u003e\n\u003cp\u003eFocus on cardiovascular, cerebrovascular, and endocrine fields facilitates specialized expertise; In 2024, the cardiovascular drugs market was valued at about $100 billion.\u003c\/p\u003e\n\u003cp\u003eStrong R\u0026amp;D indicates dedication to innovation; $50 million invested in 2024. Active manufacturing ensures production quality and controls costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003e2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiverse Product Portfolio\u003c\/td\u003e\n\u003ctd\u003eCovers APIs, pharmaceuticals, medical devices\u003c\/td\u003e\n\u003ctd\u003e15% Revenue Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialized Expertise\u003c\/td\u003e\n\u003ctd\u003eFocus on key disease areas\u003c\/td\u003e\n\u003ctd\u003e$100B Cardiovascular Market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Capabilities\u003c\/td\u003e\n\u003ctd\u003eInnovation and product pipeline\u003c\/td\u003e\n\u003ctd\u003e$50M Investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Proficiency\u003c\/td\u003e\n\u003ctd\u003eEstablished processes; in-house control\u003c\/td\u003e\n\u003ctd\u003e12% Output Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Presence\u003c\/td\u003e\n\u003ctd\u003eRobust distribution and base\u003c\/td\u003e\n\u003ctd\u003e15% Sales increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential Dependency on Specific Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHubei Biocause's concentrated focus, while offering expertise, poses risks. Over-reliance on cardiovascular, cerebrovascular, and endocrine products could backfire. A shift in these specific market demands could hurt the company. In 2024, the global cardiovascular drugs market reached $76.8B, highlighting potential vulnerability. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical faces the pharmaceutical industry's complex regulatory hurdles. Compliance with standards for manufacturing, R\u0026amp;D, and sales is costly. Non-compliance risks penalties and product recalls. The global pharmaceutical market was valued at $1.48 trillion in 2022 and is expected to reach $1.94 trillion by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition Intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe pharmaceutical market is fiercely competitive, with many global and local companies vying for market share. Intense competition can squeeze Hubei Biocause's prices and profits. Maintaining a competitive edge needs substantial investment in research and development. For example, in 2024, the global pharmaceutical market was valued at approximately $1.5 trillion, indicating the scale of competition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D Cost and Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical faces considerable R\u0026amp;D expenses and risks in its operations. The pharmaceutical industry is known for its high R\u0026amp;D costs, with potential failures. These investments can strain the company’s financial resources if product launches aren't successful. Drug development timelines are lengthy, creating uncertainty. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, the average cost to develop a new drug was estimated to be over $2.6 billion, according to the Tufts Center for the Study of Drug Development.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe success rate of drugs entering clinical trials is less than 12%, as per a 2024 study by the Biotechnology Innovation Organization (BIO).\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Vulnerabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHubei Biocause Pharmaceutical's supply chain faces vulnerabilities due to reliance on external suppliers. Disruptions from geopolitical events, natural disasters, or supplier issues could hinder production and product availability. Managing a complex global supply chain demands strong logistics and risk management strategies. For example, in 2024, supply chain disruptions cost the pharmaceutical industry an estimated $15 billion. These disruptions can lead to increased costs and decreased market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eDependence on external suppliers for key materials.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eVulnerability to geopolitical instability affecting suppliers.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRisk of production delays due to supply chain disruptions.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNeed for robust logistics and risk management.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRisks Facing the Pharmaceutical Company: A Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHubei Biocause's narrow product focus increases its market risks, with vulnerability if demand shifts. The high regulatory hurdles and costs for compliance also pose significant challenges. Stiff competition requires large investments in R\u0026amp;D. Moreover, reliance on external suppliers creates supply chain vulnerabilities.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eDetails\u003c\/th\u003e\n\u003cth\u003eFinancial Impact\/Risk\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentrated Product Portfolio\u003c\/td\u003e\n\u003ctd\u003eReliance on specific therapeutic areas, cardiovascular, etc.\u003c\/td\u003e\n\u003ctd\u003eMarket demand shifts may reduce sales; $76.8B (2024) global market vulnerability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Complexities\u003c\/td\u003e\n\u003ctd\u003eCostly compliance with manufacturing, R\u0026amp;D standards, and potential recalls.\u003c\/td\u003e\n\u003ctd\u003eIncreases operational costs; potential penalties; $1.48T (2022) growing to $1.94T (2028).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntense Competition\u003c\/td\u003e\n\u003ctd\u003eGlobal and local companies competing.\u003c\/td\u003e\n\u003ctd\u003ePressure on prices, R\u0026amp;D investments.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\/Risks\u003c\/td\u003e\n\u003ctd\u003eHigh costs with the possibility of product failures.\u003c\/td\u003e\n\u003ctd\u003e$2.6B average drug development costs; under 12% success in clinical trials.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply Chain Vulnerabilities\u003c\/td\u003e\n\u003ctd\u003eReliance on external suppliers.\u003c\/td\u003e\n\u003ctd\u003eDisruptions can hurt production and market share; $15B in pharmaceutical disruption cost.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069485986176,"sku":"biocause-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/biocause-swot-analysis.png?v=1749390704","url":"https:\/\/swotanalysistemplates.com\/products\/biocause-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}